TransCode Therapeutics Inc [NASDAQ: RNAZ] price surged by 45.45 percent to reach at $0.35.
The one-year RNAZ stock forecast points to a potential upside of 94.4. The average equity rating for RNAZ stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on TransCode Therapeutics Inc [RNAZ]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNAZ shares is $20.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNAZ stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for TransCode Therapeutics Inc is set at 0.79 The Price to Book ratio for the last quarter was 0.35, with the Price to Cash per share for the same quarter was set at 2.70.
RNAZ Stock Performance Analysis:
TransCode Therapeutics Inc [RNAZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 44.00. With this latest performance, RNAZ shares dropped by -88.05% in over the last four-week period, additionally sinking by -90.30% over the last 6 months – not to mention a drop of -95.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNAZ stock in for the last two-week period is set at 31.30, with the RSI for the last a single of trading hit 29.73, and the three-weeks RSI is set at 34.63 for TransCode Therapeutics Inc [RNAZ]. The present Moving Average for the last 50 days of trading for this stock 5.1362, while it was recorded at 0.8490 for the last single week of trading, and 13.5672 for the last 200 days.
Insight into TransCode Therapeutics Inc Fundamentals:
TransCode Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.58 and a Current Ratio set at 1.58.
RNAZ Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNAZ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TransCode Therapeutics Inc go to 78.85%.
TransCode Therapeutics Inc [RNAZ] Institutonal Ownership Details
There are presently around $22.36%, or 23.55%% of RNAZ stock, in the hands of institutional investors.
